gonads Flashcards
menopause: define menopause and climacteric, explain the clinical features, summarise treatment options including the advantages and disadvantages
define menopause
permanent cessation of menstuation due to loss of ovarian follicular activity
average age of menopause
51 (range from 45-55)
define climacteric
transition period to menopause, where periods become irregular
2 major symptoms of menopause
hot flushes (head, neck, upper chest), urogenital atrophy and dyspareunia (difficult/painful sexual intercourse)
4 other symptoms of menopause
sleep disturbance (most common), depression, decreased libido, joint pain
normal hypothalamo-pituitary gonadal axis
hypothalamus -> GnRH -> anterior pituitary -> LH and FSH -> ovaries -> oestradiol and inhibin B -> negative feedback on hypothalamus and pituitary
hypothalamo-pituitary gonadal axis: hormonal changes during menopause
hypothalamus -> GnRH -> anterior pituitary -> increased LH and FSH -> ovaries -> reduced release of oestradiol and inhibin B -> reduced negative feedback on hypothalamus and pituitary
2 complications of menopause
osteoporosis, cardiovascular risk
why does menopause cause osteoporosis, and effect on fracture risk
oestrogen deficiency causing loss of bone matrix; 10-fold increased fracture risk
menopause effect on cardiovascular disease risk
protected against CVD before menopause due to oestrogen, but have same risk as men by age of 70
how can vasomotor symptoms (hot flushes) be controlled in menopause
hormone replacement therapy (always weigh risk and benefits)
hormonal replacement therapy: what does oestrogen promote
endometrial proliferation
hormonal replacement therapy: risk of using oestrogen, and why use combined oestrogen and progesterone
endometrial carcinoma, so combined to prevent endometrial hyperplasia
what hormone replacement therapy would be prescribed following a hysterectomy
oestogen only as no endometrium as no uterus
2 hormone replacement therapy formulations and when given
cyclical: oestrogen everyday and progestogens every 12-14 days; continuous combined
hormone replacement therapy formulations: 4 oestrogen preparations (amount, administration and how often)
oral estradiol (1mg), oral conjugated equine oestrogen (0.625 mg), transdermal (patch) oestradiol (50 microgram/day), intravaginal
2 pharmacokinetic features of oestradiol
well absorbed but low bioavailability (majority undergoes first pass metabolism) so much higher dose vs transdermal skin patch or ethinyl oestradiol
what is estrone sulphate
“conjugated” oestrogen
what is ethinyl oestradiol and what does the ethinyl group do
semi-synthetic oestrogen; ethinyl group protects molecule from first pass metabolism
besides enteral, how else can more oestrogens be administered
via transdermal skin patches, so require lower dose
5 side effects of hormone replacement therapy
breast cancer, coronary heart disease, deep vein thrombosis, stroke, gallstones
absolute risk of complications for healthy symptomatic postmenopausal women in 50s taking hormone replacement therapy for 5 years
very low
hormone replacement therapy and coronary heart disease: what is important
timing of exposure (mean age in one study was 63 years, not a 50 year old)
hormone replacement therapy and coronary heart disease: risk in younger menopausal women, or women < 10 years since menopause, or 50-59 years
no excess risk
effect of oestrogen and synthetic progestins on lipid profile and endothelial function
oestrogen has beneficial effects on lipid profile and endothelial function (females have fewer CVD than men), but synthetic progestins negate these effects
effects of oestrogen and synthetic progestins in older women (>60) with atherosclerosis, and effect on CVD risk
increased prothrombotic and proinflammatory effects, increasing CVD risk
what is tibolone and what actions does it have
synthetic prohormone with oestrogenic, progestogenic and weak androgenic actions
effect of tibolone on fracture risk
reduces fracture risk
2 risks of using tibolone
increases stroke risk, possibly increases breast cancer risk
what is raloxifene
selective oestrogen receptor modulator
raloxifene oestrogenic effects in bone
reduces risk of vertebral fractures
raloxifene anti-oestrogenic effects in breat and uterus
reduces breast cancer risk
2 drawbacks of raloxifene
doesn’t reduce vasomotor symptoms of menopause (must treat with HRT), and increases risk of venous thromboembolism and fatal stroke
tamoxifen effect on breast tissue and subsequent use
anti-oestrogenic effect, so used to treat oestrogen-dependent breast tumours and metastatic breast cancers
define premature ovarian insufficiency, and % women affected
where menopause occurs before age of 40; occurs in 1% of women
4 causes of premature ovarian insufficiency
autoimmune, surgery, chemotherapy, radiation